Patent · US Active

Method of treating autoimmune disease with mesenchymal stem cells

US8481022B2 · kind B2 · utility

10Cited by

19References

22Claims

0Family size

Assignee

Genzyme Corporation · US

Inventors

Tracey Lodie · Northbridge, US
Michele Youd · Lexington, US
Ross A. Tubo · Quincy, US
Scott Eisenbeis · Lowell, US

Key dates

Filing date	Jul 28, 2011
Grant date	Jul 9, 2013
Priority date	—
Expiry date	Jul 28, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes (T1D) diagnosis or prior to the onset of disease in a subject determined to be at high risk for T1D.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.